Free Trial

Humana (HUM) Stock Price, News & Analysis

$315.29
+3.49 (+1.12%)
(As of 09/18/2024 ET)

About Humana Stock (NYSE:HUM)

Key Stats

Today's Range
$311.28
$317.63
50-Day Range
$311.85
$404.52
52-Week Range
$298.61
$530.54
Volume
1.76 million shs
Average Volume
1.64 million shs
Market Capitalization
$37.99 billion
P/E Ratio
19.63
Dividend Yield
1.12%
Price Target
$398.70
Consensus Rating
Hold

Company Overview

Humana Inc., together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, the company provides commercial fully-insured medical and specialty health insurance benefits comprising dental, vision, life insurance, and other supplemental health benefits, as well as administrative services only products to individuals and employer groups; military services, such as TRICARE T2017 East Region contract; and engages in the operations of pharmacy benefit manager business. Further, it operates pharmacies and senior focused primary care centers; and offers home solutions services, such as home health, hospice, and other services to its health plan members, as well as to third parties. The company sells its products through employers and employees, independent brokers and agents, sales representatives, and digital insurance agencies. The company was formerly known as Extendicare Inc. and changed its name to Humana Inc. in April 1974. Humana Inc. was founded in 1961 and is headquartered in Louisville, Kentucky.

Humana Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks

Overall MarketRank™: 100th Percentile

Humana scored higher than 100% of companies evaluated by MarketBeat, and ranked 1st out of 1,015 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Humana has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on 9 buy ratings, 12 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Humana has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Humana's stock forecast and price target.
  • Earnings Growth

    Earnings for Humana are expected to grow by 23.06% in the coming year, from $16.00 to $19.69 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Humana is 19.63, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 134.09.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Humana is 19.63, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 139.54.

  • Price to Earnings Growth Ratio

    Humana has a PEG Ratio of 2.56. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Humana has a P/B Ratio of 2.38. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Humana's valuation and earnings.
  • Percentage of Shares Shorted

    1.76% of the float of Humana has been sold short.
  • Short Interest Ratio / Days to Cover

    Humana has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Humana has recently decreased by 6.22%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Humana pays a meaningful dividend of 1.09%, higher than the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    Humana does not have a long track record of dividend growth.

  • Dividend Coverage

    The dividend payout ratio of Humana is 22.04%. This payout ratio is at a healthy, sustainable level, below 75%.

  • Dividend Sustainability

    Based on earnings estimates, Humana will have a dividend payout ratio of 17.98% next year. This indicates that Humana will be able to sustain or increase its dividend.

  • Read more about Humana's dividend.
  • Percentage of Shares Shorted

    1.76% of the float of Humana has been sold short.
  • Short Interest Ratio / Days to Cover

    Humana has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Humana has recently decreased by 6.22%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Humana has a news sentiment score of 0.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 16 news articles for Humana this week, compared to 19 articles on an average week.
  • Search Interest

    Only 24 people have searched for HUM on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    Only 3 people have added Humana to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Humana insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 0.32% of the stock of Humana is held by insiders.

  • Percentage Held by Institutions

    92.38% of the stock of Humana is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Humana's insider trading history.

HUM Stock News Headlines

Photo of an AI customer service robot rep with headphones and a computer.
Verint Systems' AI Bots Revolutionize Customer Service Efficiency (HUM)
Verint's AI bots help automate customer service, cutting call times and improving efficiency, making it a key player in AI-driven customer experience solutions.
Man who Predicted Trump 2016 Win: “Prepare for Election Meltdown”
Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.
Humana's Falling Share Price Gives Investors An Opportunity
Stocks on Sale Include Humana and Conagra
Humana Unusual Options Activity For September 10
See More Headlines

HUM Stock Analysis - Frequently Asked Questions

Humana's stock was trading at $457.81 at the beginning of the year. Since then, HUM shares have decreased by 31.1% and is now trading at $315.29.
View the best growth stocks for 2024 here
.

Humana Inc. (NYSE:HUM) released its quarterly earnings data on Wednesday, July, 31st. The insurance provider reported $6.96 earnings per share for the quarter, topping the consensus estimate of $5.89 by $1.07. The business's quarterly revenue was up 10.4% on a year-over-year basis.
Read the conference call transcript
.

Humana subsidiaries include these companies: Enclara Healthcare, Kindred Healthcare, American Eldercare, FPG, Metropolitan Health Networks, Certify Data Systems, Harris Rothenberg International, and more.

Top institutional investors of Humana include Pzena Investment Management LLC (1.92%), Davis Selected Advisers (1.92%), Marshall Wace LLP (1.18%) and Legal & General Group Plc (0.98%). Insiders that own company stock include Bruce D Broussard, David A Jr/Ky Jones, Samir Deshpande, Timothy S Huval, Joseph C Ventura, Susan M Diamond, Jorge S Mesquita and William Kevin Fleming.
View institutional ownership trends
.

Shares of HUM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Humana investors own include UnitedHealth Group (UNH), NVIDIA (NVDA), Walt Disney (DIS), Visa (V), Mastercard (MA), Alibaba Group (BABA) and Boeing (BA).

Company Calendar

Ex-Dividend for 7/26 Dividend
6/28/2024
Dividend Payable
7/26/2024
Last Earnings
7/31/2024
Today
9/18/2024
Ex-Dividend for 10/25 Dividend
9/30/2024
Dividend Payable
10/25/2024
Next Earnings (Estimated)
11/06/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Hospital & medical service plans
Sub-Industry
Managed Health Care
CUSIP
44485910
Employees
67,600
Year Founded
1961

Price Target and Rating

Average Stock Price Target
$398.70
High Stock Price Target
$579.00
Low Stock Price Target
$310.00
Potential Upside/Downside
+26.5%
Consensus Rating
Hold
Rating Score (0-4)
2.43
Research Coverage
21 Analysts

Profitability

Net Income
$2.49 billion
Pretax Margin
2.18%

Debt

Sales & Book Value

Annual Sales
$112.04 billion
Cash Flow
$32.91 per share
Book Value
$132.55 per share

Miscellaneous

Free Float
120,115,000
Market Cap
$37.99 billion
Optionable
Optionable
Beta
0.50

Social Links

Should I Buy Humana Stock? HUM Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, August 27, 2024. Please send any questions or comments about these Humana pros and cons to contact@marketbeat.com.

Humana
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Humana Inc.:

  • Humana Inc. stock price is currently at $358.55, showing a positive trend in recent trading.
  • Analysts have set a consensus price target of $396.35, indicating potential for growth.
  • Fifth Third Bancorp increased its holdings in Humana by 41.7% in the second quarter, reflecting confidence in the company.
  • Recent analyst reports have upgraded Humana to "hold" and "buy" ratings, suggesting positive sentiment.
  • Institutional investors and hedge funds continue to show interest in Humana, with significant stakes in the company.

Humana
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Humana Inc. for these reasons:

  • Humana's P/E ratio of 22.33 may indicate the stock is currently overvalued.
  • The company's beta of 0.51 suggests lower volatility compared to the market average, potentially limiting short-term gains.
  • While some analysts have upgraded Humana, others have maintained a "neutral" rating, indicating mixed opinions on the stock.
  • Debt-to-equity ratio of 0.70 may raise concerns about the company's financial leverage.
  • Despite recent positive movements, Humana's stock has faced resistance at certain price levels, signaling potential challenges ahead.

This page (NYSE:HUM) was last updated on 9/18/2024 by MarketBeat.com Staff
From Our Partners